Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Monitoring Changes in Intraocular Pressure After Intravitreal Injection
Authors not listed
Assiut University · 2026
Abstract
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections introduce additional fluid volume into the eye, which can cause an acute, transient elevation in intraocular pressure (IOP). The purpose of this prospective observational study is to evaluate the immediate and early changes in intraocular pressure following intravitreal anti-VEGF injections and to determine how rapidly pressure recovers toward baseline levels.
Adult participants scheduled to receive routine intravitreal anti-VEGF therapy for established clinical indications, such as diabetic macular edema, neovascular age-related macular degeneration, or retinal vein occlusion, will be enrolled. Intraocular pressure will be measured using an Icare rebound tonometer with single-use disposable probes before injection (baseline) and at 1 minute, 5 minutes, and 20 minutes post-injection. The study will also analyze whether factors such as refractive error, the number of prior injections, or the type of anti-VEGF drug administered affect the severity of post-injection pressure spikes and subsequent recovery.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-09 MST
Cite this
APA
Anonymous. (2026). Monitoring Changes in Intraocular Pressure After Intravitreal Injection. <em>Assiut University</em>. https://clinicaltrials.gov/study/NCT07826286
Vancouver
Anonymous. Monitoring Changes in Intraocular Pressure After Intravitreal Injection. Assiut University. 2026.
BibTeX
@misc{anon2026Monito,
title = {Monitoring Changes in Intraocular Pressure After Intravitreal Injection},
author = {Anonymous},
journal = {Assiut University},
year = {2026},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Rishi Singh 2012
Open access · US-GOV
A Single Arm, Investigator Initiated Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Injection in Subjects With Exudative Age-related Macular Degeneration Previously Treated With Ranibizumab or Bevacizumab (ASSESS Study)
Bayer 2017
Open access · US-GOV
An Observational Study to Assess the Use of Intravitreal Aflibercept Injections in a Routine "Treat and Extend" Regimen in Treatment-naïve Patients Diagnosed With Wet Age-related Macular Degeneration
University of Malaya 2012
Open access · US-GOV
Effect of Intravitreal Anti-Vascular Endothelial Growth Factors on Retinal Vessels Diameter
Bayer 2021
Open access · US-GOV
Assessment of the Safety and Drug Utilization of Intravitreal Aflibercept Injection in Mexican Routine Clinical Practice for the Treatment of Wet Age Related Macular Degeneration (wAMD), Diabetic Macular Edema (DME), Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO), Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO) and Myopic Neovascularization (mCNV). A Post-authorization Safety Study (PASS).
Jiangsu T-Mab Biopharma Co.,Ltd 2017
Open access · US-GOV
A Multi-center, Open-label Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-Related Macular Degeneration
Bayer 2018
Open access · US-GOV